The biotech industry is finally beginning to come around to the idea of Artificial Intelligence (A.I.). 

Various innovators, including Elon Musk views A.I. as a cornerstone of the healthcare industry, reports BioSpace. The company, who are the brains behind SpaceX and Tesla, launched the biotech company Neuralink, whose ultimate goal is to link the human brain with a computer. Their idea is to implant computers into a human brain as a way to merge man-made software with the power of the brain in order to improve memory or as a way to interface with computers. 

In addition, Neuralink is currently developing a technology called “neural lace” that would allow the brain to communicate with a computer without having to physically interface with it. 


Following in the same footsteps, MyndYou has created an artificial intelligence diagnostics tool to track the subtle changes in speech patterns of Alzheimer’s patients. The technology encompasses a unique method for analysing multiple parametres related to change in cognition that are collected as part of day to day life, which includes speech patterns. At present, the program is being tested through a collaboration with Massachusetts General Hospital. The study will validate MyndYou’s technology for the remote, automated detection of subtle changes in speech patterns of Alzheimer’s patients. 

In July, the Mayo Clinic and nference launched a startup company called Qrativ that is focused on drug development that will be powered by clinical expertise and artificial intelligence. They will use the technology to discover and develop treatments for diseases with unmet medical need. 

Murali Aravamudan, co-founder and chief executive officer at Qrativ and nference, explained, “Our core technology based on a neural network ensemble identifies nascent drug-disease, drug-gene and other therapeutically-relevant associations from the vast biomedical literature. The spatio-temporal signs are triangulated with real world-phenotypic and molecular evidence amassed from systemic and longitudinal patient care, which we believe can significantly accelerate drug discovery and development.”

As a result of the increased adoption of artificial intelligence and machine learning within the biotech industry, more career paths are going to open up. Companies are willing to spend big money when it comes to hiring the best possible people for the projects.